Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant

Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant

Introduction. Liver transplant (LT) is a widely accepted treatment for hepatocellular carcinoma (HCC). The role of neoadjuvant (NAT) is still under debate.The aim of the work is to assess the effect of NAT on relapse-free survival (RFS) and overall survival (OS) in patients with HCC who underwent LT...

Full description

Bibliographic Details
Main Authors: A. A. Pitkevich, V. Yu. Kosyrev, I. A. Dzhanyan, M. S. Novruzbekov, A. R. Monakhov, S. I. Zubenko, S. E. Voskanyan, V. S. Rudakov, E. A. Moroz, V. V. Breder
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-12-01
Series:Медицинский совет
Subjects:
hepatocellular cancer
liver transplantation
neoadjuvant therapy
tace
rfa
Online Access:https://www.med-sovet.pro/jour/article/view/6587

Internet

https://www.med-sovet.pro/jour/article/view/6587

Similar Items